Cerenome, Inc. CNSY
0.80 USD +0.12 (+18.12%)
At closeNov 11, 2026, 7:30 PM EST
0.81 +0.01 +1.00%
After hours · Nov 11, 7:30 PM ET
0.68 Day range 0.9015
0.43 52-week range 19.00
- YTD
- -93.72%
- 1 year
- -94.38%
- Market cap
- 6.08M
- EPS (ttm)
- -3.36
- YTD return
- -93.72%
- 1-year return
- -94.38%
- Volume
- 366.50K
- Avg volume
- 644.45K
- Open
- 0.705
- Previous close
- 0.6781
- Day's range
- 0.68 – 0.9015
- 52-week range
- 0.43 – 19.00
5D -0.0330 (-3.96%)
Financials — quick view
CNSY Revenue — quarterly 411.00K
CNSY Net income — quarterly -9.01M
CNSY EPS — quarterly -1.31
News
Cerenome Appoints Director Ron Andrews as Chief Business Officer 
12 Health Care Stocks Moving In Wednesday's Intraday Session 
CNSide Diagnostics Inks National In-Network Laboratory Ancillary Provider With Aetna Health Plans 
Cerenome Secures National In-Network Agreement with Aetna for CNSide® - 12 Health Care Stocks Moving In Tuesday's Intraday Session
Cerenome Completes Enrollment in Phase 2 ReSPECT-GBM Trial of REYOBIQ™ in Recurrent Glioblastoma 
Cerenome To Report Poster Presentation Of Interim Data From Its Current ReSPECT-LMM Multidose Trial Of REYOBIQ At 31st Annual Meeting And Education Day 
Cerenome to Present Interim Clinical Update on the ReSPECT-LM Trial of Multiple REYOBIQ™ Doses in Leptomeningeal Metastases 
New Strong Sell Stocks for October 22nd - Cerenome Presents New Preclinical Data At 16th Biennial Rivkin Ovarian Cancer Research Symposium Regarding Immunomodulatory Properties Of REYOBIQ
Your note
Sign in to keep a note on CNSY — it syncs with the Stock Master app.